Log In
Print
BCIQ
Print
Print this Print this
 

CV9104

  Manage Alerts
Collapse Summary General Information
Company CureVac GmbH
DescriptionModified mRNA vaccine encoding antigens overexpressed in prostate cancer
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today